NCT01483924 is a Phase 2 clinical trial of Apo805K1 in Plaque Psoriasis, sponsored by ApoPharma.

Who is sponsoring NCT01483924?

NCT01483924 is sponsored by ApoPharma.

What drugs are being tested in NCT01483924?

Interventions in NCT01483924: Apo805K1.

What condition does NCT01483924 study?

NCT01483924 studies Plaque Psoriasis.

Is NCT01483924 still recruiting?

NCT01483924 is currently completed. Last updated 9 February 2015.

Are results published for NCT01483924?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2015-02-09 · How we verify

NCT01483924

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A 12-week Randomized, Double-blind, Placebo-controlled, Multicenter, Multiple Sequential Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed Phase 2 Results posted Last updated 9 February 2015

What this trial tests

Phase 2 trial testing Apo805K1 in Plaque Psoriasis in 60 participants. Completed in 1 October 2013.

Timeline

1 November 2011

Primary endpoint
1 August 2013

1 October 2013

Quick facts

Lead sponsor	ApoPharma
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	1 November 2011
Primary completion	1 August 2013
Estimated completion	1 October 2013
Sites	7 locations across United States, Canada

Drugs / interventions tested

Apo805K1 — full drug profile →

Conditions studied

Plaque Psoriasis — all drugs for Plaque Psoriasis →

Sponsor

ApoPharma — full company profile →

Who can join

Adults 18 to 65, any sex, with Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Patients With Adverse Events
Time frame: 12 Weeks
The number of patients in each treatment group who reported at least 1 adverse event, including clinically significant changes from baseline in vital signs, 12-lead ECG, physical examinations and laboratory tests, from the time of the first dose until the last study visit.

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of 12 weeks of treatment with Apo805K1 in subjects with moderate to severe chronic plaque psoriasis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Plaque Psoriasis

Currently open trials in the same condition.

NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor · Phase 3 · recruiting
NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis · Phase 3 · recruiting
NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting

Other ApoPharma trials

Trials by the same sponsor.

NCT03802916 — Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload · Phase 2 · completed
NCT02728843 — Study of Parkinson's Early Stage With Deferiprone · Phase 2 · completed
NCT02443545 — Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias · Phase 4 · terminated
NCT02041299 — Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias · Phase 4 · terminated
NCT01741532 — Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN) · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01483924 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ApoPharma
Last refreshed: 9 February 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01483924.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing